Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
Nolan-Stevaux O, Li C, Liang L, Zhan J, Estrada J, Osgood T, Li F, Zhang H, Case R, Murawsky CM, Estes B, Moore GL, Bernett MJ, Muchhal U, Desjarlais JR, Staley BK, Stevens J, Cooke KS, Aeffner F, Thomas O, Stieglmaier J, Lee JL, Coxon A, Bailis JM. Nolan-Stevaux O, et al. Among authors: desjarlais jr. Cancer Discov. 2024 Jan 12;14(1):90-103. doi: 10.1158/2159-8290.CD-23-0984. Cancer Discov. 2024. PMID: 37861452
Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy.
Yadav R, Schubbert S, Holder PG, Chiang EY, Kiabi N, Bogaert L, Leung I, Rashid R, Avery KN, Bonzon C, Desjarlais JR, Sanjabi S, Sharma A, Lepherd M, Shelton A, Chan P, Liu Y, Joslyn L, Hosseini I, Stefanich EG, Kamath AV, Bernett MJ, Shivva V. Yadav R, et al. Among authors: desjarlais jr. Front Pharmacol. 2024 Jun 3;15:1380000. doi: 10.3389/fphar.2024.1380000. eCollection 2024. Front Pharmacol. 2024. PMID: 38887559 Free PMC article.
A B7-H3-targeted CD28 bispecific antibody enhances the activity of anti-PD1 and CD3 T-cell engager immunotherapies.
Moore GL, Zeng VG, Diaz JE, Bonzon C, Avery KN, Rashid R, Qi J, Nam DH, Jacinto J, Dragovich MA, Kim YK, Balcazar KP, Bakhit CG, Eivazi A, Nguyen H, Muchhal US, Szymkowski DE, Desjarlais JR, Hedvat M. Moore GL, et al. Among authors: desjarlais jr. Mol Cancer Ther. 2024 Sep 20. doi: 10.1158/1535-7163.MCT-24-0327. Online ahead of print. Mol Cancer Ther. 2024. PMID: 39301613
Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022.
Atyeo C, Slein MD, Fischinger S, Burke J, Schäfer A, Leist SR, Kuzmina NA, Mire C, Honko A, Johnson R, Storm N, Bernett M, Tong P, Zuo T, Lin J, Zuiani A, Linde C, Suscovich T, Wesemann DR, Griffiths A, Desjarlais JR, Juelg BD, Goudsmit J, Bukreyev A, Baric R, Alter G. Atyeo C, et al. Among authors: desjarlais jr. JCI Insight. 2021 Jan 11;6(1):e143129. doi: 10.1172/jci.insight.143129. JCI Insight. 2021. PMID: 33427208 Free PMC article.
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL, Fajardo F, Zhong W, Bernett MJ, Muchhal US, Moore GL, Stevens J, Case R, Pearson JT, Liu S, McElroy PL, Canon J, Desjarlais JR, Coxon A, Balazs M, Nolan-Stevaux O. Zuch de Zafra CL, et al. Among authors: desjarlais jr. Clin Cancer Res. 2019 Jul 1;25(13):3921-3933. doi: 10.1158/1078-0432.CCR-18-2752. Epub 2019 Mar 27. Clin Cancer Res. 2019. PMID: 30918018
Redirected T Cell Cytotoxicity in Cancer Therapy.
Clynes RA, Desjarlais JR. Clynes RA, et al. Among authors: desjarlais jr. Annu Rev Med. 2019 Jan 27;70:437-450. doi: 10.1146/annurev-med-062617-035821. Epub 2018 Oct 31. Annu Rev Med. 2019. PMID: 30379598 Review.
51 results